- Home
- NXTC vs TENX Comparison
NXTC vs TENX Comparison
Compare NXTC & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NXTC
- TENX
- Stock Information
- Founded
- NXTC 2015
- TENX 1967
- Country
- NXTC United States
- TENX United States
- Employees
- NXTC N/A
- TENX N/A
- Industry
- NXTC Biotechnology: Pharmaceutical Preparations
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- NXTC Health Care
- TENX Health Care
- Exchange
- NXTC Nasdaq
- TENX Nasdaq
- Market Cap
- NXTC 23.0M
- TENX 21.8M
- IPO Year
- NXTC 2019
- TENX N/A
- Fundamental
- Price
- NXTC $0.79
- TENX $6.37
- Analyst Decision
- NXTC Strong Buy
- TENX Strong Buy
- Analyst Count
- NXTC 2
- TENX 4
- Target Price
- NXTC $4.00
- TENX $20.67
- AVG Volume (30 Days)
- NXTC 201.3K
- TENX 38.7K
- Earning Date
- NXTC 11-07-2024
- TENX 11-13-2024
- Dividend Yield
- NXTC N/A
- TENX N/A
- EPS Growth
- NXTC N/A
- TENX N/A
- EPS
- NXTC N/A
- TENX N/A
- Revenue
- NXTC N/A
- TENX N/A
- Revenue This Year
- NXTC N/A
- TENX N/A
- Revenue Next Year
- NXTC N/A
- TENX N/A
- P/E Ratio
- NXTC N/A
- TENX N/A
- Revenue Growth
- NXTC N/A
- TENX N/A
- 52 Week Low
- NXTC $0.76
- TENX $2.77
- 52 Week High
- NXTC $2.57
- TENX $21.46
- Technical
- Relative Strength Index (RSI)
- NXTC 36.33
- TENX 57.59
- Support Level
- NXTC $0.76
- TENX $5.92
- Resistance Level
- NXTC $0.83
- TENX $6.65
- Average True Range (ATR)
- NXTC 0.07
- TENX 0.43
- MACD
- NXTC 0.01
- TENX -0.02
- Stochastic Oscillator
- NXTC 14.87
- TENX 56.21
About NXTC NextCure Inc.
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company's product candidates include; NC410 a fusion protein of LAIR-2, a fusion protein that, in combination with pembrolizumab, demonstrated early evidence of clinical activity in colorectal (CRC) and ovarian cancers, and LNCB74, an ADC that is directed to B7-H4, a clinically validated cancer target. The company is also seeking a partner for its other clinical programs such as NC525 and NC318 and its preclinical non-oncology programs NC605, for chronic bone diseases, and NC181, for Alzheimer's disease.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.